A New Model for Funding Cost-Effectiveness Research
Patients before profits
Public Good Pharma (PGP) works with health insurers (payers) to provide self-funding Interventional Pharmacoeconomic (IVPE) trials as a cost-containment solution, by developing lower-cost and better alternatives to expensive specialty drugs, including repurposed generics, biosimilars, dose de-escalations, & lifestyle interventions.
By targeting the most expensive treatments (including oncology and cell & gene therapies) and leveraging the cost-savings of payers to create high-quality clinical evidence under full regulatory and ethical oversight, PGP enables payers to reimburse more cost-effective therapies with no financial or legal risk. The result is lower costs, broader access, and faster, sustainable innovation in medicine, while generating significant ROI for payers.
Reduce Financial Toxicity
Improve Patient Outcomes
Our incentives are aligned with patients and payers. We generate revenue by running trials that reduce pharmaceutical spend and selling higher volumes of low-cost therapies, not charging high-margins for drugs that many or most patients cannot access. Our long-term objective is FDA approval of cost-effective therapies that improve access and sustainability.
We work with forward-thinking payers including self-insured employers, pass-through PBMs, state health plans, and integrated health systems.
Connect with us to explore how IVPE trials can save you 50-90% on the most expensive speciality drugs in your health plan.
